Quantitation of Neurodegenerative Biomarkers in Plasma Using SMC<sup>®</sup> High Sensitivity Immunoassays
MILLIPORESIGMA SPONSORED CONTENT

Quantitation of Neurodegenerative Biomarkers in Plasma Using SMC® High Sensitivity Immunoassays

Quantitation of Neurodegenerative Biomarkers in Plasma Using Single Molecule Counting (SMC) High Sensitivity Immunoassays

The ultrasensitive, high-performance SMCxPRO®  immunoassay platform enables the measurement of previously undetectable proteins, such as biomarkers of neurodegenerative disease. The study detailed in this poster reviewed the measurement of both well-established and novel biomarkers associated with Alzheimer's disease in samples of human cerebrospinal fluid (CSF) and plasma utilizing SMC® immunoassay kits. These fit-for-purpose immunoassays offer researchers unparalleled flexibility, empowering them to explore a wide array of proteins linked to Alzheimer's disease and other neurological disorders. Download this poster to learn more.

Download Now

    Please fill out the information below to download the content. If you are already registered, or have requested a quote before, and this information will be filled out for you.
  • Please enter your first and last name.

  • Please enter the name of the company or institution you work at.

  • Please enter your mailing address.

  • Please enter the e-mail address you would like to be contacted at.

  • By submitting this form, you consent to Biocompare storing your email address and contact information and transmitting your contact information to the Future Lab sponsor. You also agree to receive email from Biocompare and the sponsor. You may request to be removed at any time.